The funding comes from a syndicate which includes all Series C investors and one new investor, Chinese assay developer Wondfo Biotech.
In Nature this week: mobile phone-based targeted DNA sequencing, and more.
Singapore Eye Research Institute's Roger Beuerman wants to bring point-of-care eye diagnostics to the ophthalmologist's office.
The device, which will be tested in collaboration with a Panamanian research institute, will run 40-minute tests without the need for electricity.
The point-of-care test detects and distinguishes influenza A and B as well as respiratory syncytial virus in about 20 minutes.
Abbott's MDx sales were driven by continued strong growth in its infectious disease testing business but were partly offset by the planned scale down of its genetics business.
The firm postponed the launch to enhance Omni's capabilities, in the meantime focusing on opportunities in near-patient testing for its GeneXpert system.
QuantuMDx says its low-cost, handheld device will be able to quickly diagnose patients, as the Guardian reports.
Abbott reported Diagnostics sales of $1.12 billion, up 2 percent on a reported basis and 7 percent excluding foreign currency effects.
The company will use the funding to prepare for the 2017 launch of its DiagCore integrated molecular and immunoassay near-patient testing platform.
In Science this week: genetic target for urothelial bladder cancer treatment, and more.
At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.
Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.
Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.